Drugs in Dev.
Genetic Disease
Preclinical
Italy 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
Details : Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
